Efficacy of combined therapy in patients with hepatitis B virus-related decompensated cirrhosis

Table 2 Comparison of change in hepatic and renal function between two treatment groups (mean ± SD)

Characteristics	De novo combination group				Lamivudine monotherapy group
	Baseline	48 wk	96 wk	144 wk	Baseline	48 wk	96 wk	144 wk
Hepatic function
Albumin (g/dL)	3.2 ± 0.7	3.5 ± 0.4	3.8 ± 0.1	4.1 ± 0.3a	3.3 ± 0.6	3.4 ± 0.3	3.6 ± 0.8	3.8 ± 0.3c
TBIL (μmol/L)	38.5 ± 12.1	24.3 ± 11.4	20.4 ± 10.8	16.1 ± 6.7a	37.8 ± 11.9	26.5 ± 12.3	23.2 ± 10.5	18.1 ± 12.3
PT (s)	17.1 ± 4.5	14.5 ± 5.3	13.3 ± 9.1a	11.4 ± 5.8a	17.6 ± 3.1	15.4 ± 3.5	14.5 ± 6.9	13.4 ± 5.8c
CTP score	8.9 ± 2.1	7.0 ± 1.2	6.3 ± 2.7a	5.7 ± 1.9a	8.8 ± 1.7	7.6 ± 2.4	6.6 ± 1.9	6.1 ± 3.8
MELD score	12.4 ± 3.7	10.0 ± 6.5	9.6 ± 5.3	8.8 ± 2.7a	11.9 ± 2.5	10.8 ± 3.7	8.9.7 ± 4.8	8.9 ± 4.3
Renal function
BUN (mmol/L)	6.7 ± 0.7	6.8 ± 1.4	7.1 ± 1.1	6.9 ± 0.3	6.8 ± 0.6	7.4 ± 1.3	7.2 ± 0.8	7.0 ± 1.1
Cr (μmol/L)	96.1 ± 12.3	98.3 ± 8.9	97.8 ± 10.7	99.7 ± 9.6	95.6 ± 12.1	97.8 ± 7.9	98.6 ± 12.7	99.5 ± 9.7
GFR (mL/min)	115.2 ± 34.5	112.8 ± 56.3	103.4 ± 76.1	109.1 ± 21.5	113.5 ± 22.9	107.6 ± 13.4	112.4 ± 45.5	109.4 ± 13.4

^aP < 0.05 vs baseline combination group;

^cP < 0.05 vs lamivudine monotherapy group. TBIL: Total bilirubin; PT: Prothrombin time; CTP: Child-Turcotte-Pugh score, MELD: Model for End-Stage Liver Disease; BUN: Blood urine nitrogen; Cr: Creatinine; GFR: Glomerular filtration rate.